| Literature DB >> 33376742 |
Maryam Jalali1, Zahra Bagheri1, Najaf Zare2, Seyyed Mohammad Taghi Ayatollahi1.
Abstract
Crossover designs are commonly applied in research due to efficiency and subject parsimony compared to parallel studies. Baseline measurements would improve the power of comparison. For time to event outcomes, the sample size is reduced due to censorship, if they are ignored; thus, applying traditional regression models will be limited. A logical solution is to impute the censored observation and apply common analytical models for analyzing the data. Nevertheless, techniques to impute censored data in time-to-event outcomes in crossover designs are not practiced as much. Accordingly, we propose a method to impute the censored observation using median residual life regression and then analyze the data using analyses of covariance (ANCOVA), considering the difference of period-specific baselines as covariate. We used simulation to show the favorable performance of our method relative to a recently proposed method, multiple imputation with model averaging and ANCOVA (MIMI). Specifically, the censored observations were multiply-imputed using prespecified parametric event time models, and then, the methods were applied to a real data example.Entities:
Mesh:
Year: 2020 PMID: 33376742 PMCID: PMC7746454 DOI: 10.1155/2020/8475154
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
True θ values used in simulation study under the alternative hypothesis for each combination of distribution, mean pairwise correlation coefficient, percentage of censoring, and sample size.
| Mean pairwise correlation |
|
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of censoring | 30% | 50% | 30% | 50% | ||||||||
|
| 12 | 24 | 48 | 12 | 24 | 48 | 12 | 24 | 48 | 12 | 24 | 48 |
| Dist | ||||||||||||
| Exp | 2.33 | 1.59 | 1.6 | 2.3 | 1.8 | 1.5 | 2.1 | 1.7 | 1.5 | 2 | 1.52 | 1.35 |
| Weibull | 2.3 | 1.93 | 1.68 | 2.3 | 1.69 | 1.51 | 2 | 1.78 | 1.56 | 2 | 1.64 | 1.28 |
| Gamma | 2.1 | 1.4 | 1.3 | 1.95 | 1.65 | 1.2 | 2 | 1.4 | 1.24 | 2.1 | 1.3 | 1.14 |
Type 1 error (target is 5%) and power (%) for the multiple imputation with model averaging and analysis of covariance (MI) and our proposed method (1000 simulations).
| Mean pairwise correlation |
|
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Censoring percentage | 30% | 50% | 30% | 50% | ||||||||||
| Distribution |
| 12 | 24 | 48 | 12 | 24 | 48 | 12 | 24 | 48 | 12 | 24 | 48 | |
| Method | ||||||||||||||
| Exp | Error |
| 4.8 | 4 | 4.9 | 5 | 4.5 | 5 | 4.5 | 4.6 | 4.9 | 4.8 | 5 | 5 |
| MERL | 4.6 | 4 | 4.8 | 4.9 | 4.1 | 5 | 3.9 | 4 | 4.4 | 3.8 | 4.1 | 4.5 | ||
| Power |
| 78 | 80 | 81 | 69 | 79 | 80 | 81 | 79 | 84 | 78 | 80 | 81 | |
| MERL | 81 | 87 | 91 | 78 | 80 | 83 | 82 | 94 | 85 | 84 | 86 | 87 | ||
| Weibull | Error |
| 3.8 | 4 | 4.3 | 4 | 5 | 4 | 4.1 | 3 | 4.9 | 4.2 | 3.4 | 4.8 |
| MERL | 3.5 | 4.1 | 4 | 4.2 | 4 | 4.3 | 3.8 | 3.1 | 4 | 4 | 3.5 | 4.2 | ||
| Power |
| 79 | 80 | 81 | 72 | 80 | 81 | 79 | 80 | 78 | 81 | 79 | 80 | |
| MERL | 85 | 90 | 91 | 75 | 81 | 90 | 89 | 95 | 96 | 89 | 90 | 91 | ||
| Gamma | Error |
| 1.3 | 1.5 | 2.7 | 4.5 | 3.1 | 4.6 | 2.2 | 2.9 | 3.4 | 1.8 | 2.4 | 4.1 |
| MERL | 1 | 1.2 | 2.1 | 4.1 | 4.1 | 5 | 1.9 | 2 | 3.4 | 2 | 2.1 | 3.9 | ||
| Power |
| 77 | 80 | 79 | 75 | 78 | 80 | 81 | 81.9 | 79 | 81 | 83 | 82 | |
| MERL | 88 | 95 | 93 | 80 | 90 | 95 | 90 | 95 | 96 | 88 | 92 | 94 | ||
Percentage of bias (%) under the null and alternative hypothesis and 95% confidence interval coverage probability under the alternative hypothesis H1:θ ≠ 1 for estimating logθ for our proposed method when the covariance structure is AR (1) and the distributions are exponential (E), Weibull (W), and Gamma (G).
| Mean pairwise correlation |
|
| |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of censoring | 30% | 50% | 30% | 50% | |||||||||
| Dist |
| 12 | 24 | 48 | 12 | 24 | 48 | 12 | 24 | 48 | 12 | 24 | 48 |
|
| |||||||||||||
| E | Bias ( | −3 × 10−5 | −4 × 10−5 | 3 × 10−5 | −2 × 10−5 | −3 × 10−5 | −3 × 10−5 | 45 × 10−5 | −5 × 10−5 | 71 × 10−5 | 2 × 10−5 | 2 × 10−5 | −3 × 10−5 |
| Bias ( | 0.80 | 1 | 0.6 | 3 | 3.1 | 2.9 | 1.6 | 1.7 | 1.2 | 3 | 5 | 4.9 | |
|
| 94.5 | 94.9 | 95 | 97 | 95 | 94.4 | 95.3 | 95 | 96.5 | 96 | 95.5 | 97 | |
|
| |||||||||||||
| W | Bias ( | 4 × 10−5 | 3 × 10−5 | 68 × 10−6 | −1 × 10−5 | −2 × 10−5 | 3 × 10−5 | 4 × 10−5 | −3 × 10−5 | 5 × 10−5 | 5 × 10−5 | 2 × 10−5 | −2 × 10−5 |
| Bias ( | 0.6 | 0.82 | 0.5 | 2.5 | 2.7 | 2.9 | 1.5 | 1.7 | 1.3 | 2.8 | 4.9 | 5 | |
|
| 95 | 95.1 | 96 | 96 | 96.7 | 95 | 96 | 97 | 96.7 | 97 | 96 | 94.5 | |
|
| |||||||||||||
| G | Bias ( | 1 × 10−5 | 2 × 10−5 | −3 × 10−5 | −5 × 10−5 | 1 × 10−5 | 4 × 10−5 | 2 × 10−5 | −2 × 10−5 | 5 × 10−5 | 0 × 10−5 | 0 × 10−5 | 3 × 10−5 |
| Bias ( | -6.1 | -5.5 | -4.9 | -8.2 | -6.5 | -5.5 | -5.4 | -4.1 | -3.5 | -7.9 | -8.5 | -9 | |
|
| 95.1 | 94 | 95 | 95.3 | 94.2 | 95.1 | 95.5 | 94.4 | 95.2 | 96 | 95.3 | 95.1 | |
Event times (min) for a 10 min treadmill test in a 2 × 2 crossover clinical trial.
| Placebo-drug sequence | Drug-placebo sequence | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Period 1 (placebo) | Period 2 (drug) | Period 1 (drug) | Period 2 (placebo) | ||||||
| Subject (age) | X1 | Y1 | X2 | Y2 | Subject (age) | X1 | Y1 | X2 | Y2 |
| 1 (52.91) | 1.5 | 1 | 1 | 1.5 | 2 (65) | 1 | 1 | 1 | 2.5 |
| 3 (45.79) | 6 | 4 | 3.5 | >10 | 4 (40) | 6 | >10 | 2.5 | 2.5 |
| 5 (64.37) | 1 | 1 | 1.5 | 4.5 | 6 (59.08) | 3 | 2 | 1 | .5 |
| 7 (54.13) | 3.5 | 1.5 | .5 | 3 | 8 (63.46) | 2.5 | 2.5 | 1.5 | 2 |
| 9 (61.14) | .5 | 1 | 3.5 | 8 | 10 (51.78) | 2 | 2.5 | 2.5 | 3 |
| 11 (47.59) | 6 | 10 | 6 | >10 | 12 (58.59) | 1.5 | 4.5 | 2.5 | 1 |
| 13 (70) | .5 | .5 | 1 | >10 | 14 (55.08) | 3.5 | 5.5 | 4.5 | 9.5 |
| 15 (57.28) | 1 | 1 | 1 | 2.5 | 16 (65.16) | 1 | 2 | 2 | >10 |
| 17 (59.75) | 1.5 | 1 | .5 | .5 | 18 (41.34) | 6 | >10 | 5 | 3.5 |
| 19 (67.77) | 1 | 1.5 | 2 | 4 | 20 (59.44) | 2 | 3 | 1.5 | 1.5 |
| 21 (42.91) | 5 | 5.5 | 3 | 1.5 | 22 (65.54) | 1.5 | 2.5 | 1.5 | .5 |
| 23 (50.72) | 2.5 | 5 | 6 | 4.5 | 24 (70) | 1.5 | 3.5 | 2.5 | 3 |
| 25 (47.01) | 5 | 5.5 | 4.5 | 6 | 26 (55.63) | 3.5 | 9 | 6 | 6 |
| 27 (62.26) | 1 | 2 | 2.5 | 8.5 | 28 (62.93) | 2 | 5.5 | 3.5 | 8 |
| 29 (40) | 5 | 5.5 | 3.5 | 2 | 30 (56.67) | 2.5 | 2.5 | 1 | .5 |
| 31 (66.27) | .5 | 1 | 2 | 7.5 | 32 (63.13) | 2.5 | 3.5 | 2.5 | 4 |
| 33 (48.16) | 5 | 4 | 2 | 2 | 34 (41.62) | 5.5 | 3 | 1 | .5 |
| 35 (65.04) | .5 | .5 | 1 | 1.5 | 36 (55.70) | 3 | 5.5 | 5 | .5 |
| 37 (66.49) | 1.5 | 2 | 3 | 3 | 38 (66.62) | .5 | 1 | 1 | 5.4 |
| 39 (43.19) | 6 | 4 | 1.5 | .5 | 40 (53.10) | 2.5 | 5 | 2.5 | .5 |
| Median | 1.5 | 1.75 | 2 | 3.5 | Median | 2.5 | 3.25 | 2.5 | 2.5 |
X1: baseline response in period 1; Y1: posttreatment response in period 1; X2: baseline response in period 2; Y2: posttreatment response in period 2.
Estimated survival time of censored observations in treadmill test for the multiple imputation method, the proposed method, and the proposed method by adding age to the model.
| Placebo-drug sequence | Drug-placebo sequence | ||||
|---|---|---|---|---|---|
| Model | Subject (age) | Period 2 (drug) | Subject | Period 1 (drug) | Period 2 (placebo) |
| Y2 | Y1 | Y2 | |||
| Multiple imputation | 3 | 14.14 ± 0.35 | 4 | 14.41 ± 0.39 | _ |
| 11 | 21.46 ± 0.40 | 16 | _ | 10.63 ± 0.37 | |
| 13 | 10.62 ± 0.41 | 18 | 23.34 ± 0.51 | _ | |
| MERL | 3 | 15 ± 0.30 | 4 | 15.1 ± 0.33 | _ |
| 11 | 23 ± 0.38 | 16 | _ | 11.47 ± 0.32 | |
| 13 | 11.5 ± 0.40 | 18 | 24.58 ± 0.48 | _ | |
| MERL (adding age) | 3 (45.79) | 16.1 ± 0.28 | 4 (40) | 16.1 ± 0.31 | _ |
| 11 (47.58) | 24 ± 0.31 | 16 (65.16) | _ | 12.5 ± 0.30 | |
| 13 (70) | 12.2 ± 0.35 | 18 (41.34) | 25.1 ± 0.43 | _ | |
Y1: posttreatment response in period 1; Y2: posttreatment response in period 2.